Abcam, ab250473, Anti-TPD52 antibody [EPR14219] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal TPD52 antibody. Carrier free. Suitable for WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14219,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, ICC/IF, Flow Cyt (Intra), IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250473 is the carrier-free version of
ab181260
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Tumor Protein D52 (TPD52) is a 224 amino acid protein also known as PrLZ or D52-like protein 1 with a mass of approximately 23 kDa. TPD52 features prominently in the regulation of cell proliferation and vesicle trafficking. It is expressed in a wide range of tissues with significant expression levels in the pancreas prostate and various cancers. TPD52 associates with other members of the D52 family proteins forming homo- or heterodimers that play a part in its function.
Biological function summary
TPD52 is involved in cellular processes like growth apoptosis and exocytosis. It often forms part of protein complexes assisting in intracellular signaling pathways and vesicular transport mechanisms. The ability of TPD52 to interface with other proteins such as 14-3-3 or annexins provides it with diverse functionality. Moreover its involvement in regulating secretory pathways underlines its importance in different cell types particularly those with high secretion activity.
Pathways
TPD52 integrates into the MAPK and calcium signaling pathways. The MAPK pathway which includes key proteins like ERK1/2 involves TPD52 in processes affecting cell growth and differentiation. TPD52 can act upstream or downstream of MAPK components indicating its dynamic role in the pathway. Similarly in calcium signaling TPD52 interacts with annexins which position it within calcium-dependent exocytotic events and cellular responses dependent on Ca2+ dynamics.
TPD52 shows an association with cancers such as prostate and breast cancer. In breast cancer its overexpression correlates with rapid tumor growth and decreased patient survival rates. TPD52's link to the protein AKT suggests a role in oncogenic pathways where AKT promotes cell survival and growth. Similarly in prostate cancer altered expression levels of TPD52 may enhance tumorigenic potential and aggressiveness establishing TPD52 as a potential therapeutic target for cancer treatments.